ATE197126T1 - Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien - Google Patents

Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien

Info

Publication number
ATE197126T1
ATE197126T1 AT92918805T AT92918805T ATE197126T1 AT E197126 T1 ATE197126 T1 AT E197126T1 AT 92918805 T AT92918805 T AT 92918805T AT 92918805 T AT92918805 T AT 92918805T AT E197126 T1 ATE197126 T1 AT E197126T1
Authority
AT
Austria
Prior art keywords
sublingual
therapeutic agents
buccal administration
compounds
methods
Prior art date
Application number
AT92918805T
Other languages
English (en)
Inventor
Lu Mou-Ying Fu
Thomas L Reiland
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE197126T1 publication Critical patent/ATE197126T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92918805T 1991-08-26 1992-08-18 Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien ATE197126T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75084391A 1991-08-26 1991-08-26
PCT/US1992/006944 WO1993003751A1 (en) 1991-08-26 1992-08-18 Compositions and methods for the sublingual or buccal administration of therapeutic agents

Publications (1)

Publication Number Publication Date
ATE197126T1 true ATE197126T1 (de) 2000-11-15

Family

ID=25019382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918805T ATE197126T1 (de) 1991-08-26 1992-08-18 Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien

Country Status (14)

Country Link
US (1) US5284657A (de)
EP (1) EP0601053B1 (de)
JP (1) JPH06510046A (de)
KR (1) KR100256715B1 (de)
AT (1) ATE197126T1 (de)
AU (1) AU669856B2 (de)
CA (1) CA2103163C (de)
DE (1) DE69231536T2 (de)
DK (1) DK0601053T3 (de)
ES (1) ES2153362T3 (de)
GR (1) GR3035116T3 (de)
IL (1) IL102857A (de)
PT (1) PT100812B (de)
WO (1) WO1993003751A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP1525858A1 (de) * 1995-06-07 2005-04-27 Durect Corporation Kontrolliertes Zuführsystem mit einer Flüssigkeit von hoher Viskosität
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
DE69636706T2 (de) * 1995-09-25 2007-10-11 Ashmont Holdings Ltd., Takapuna Makrocyclische lacton anthelmintika
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
EP0880969A1 (de) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Im physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
WO1999016417A1 (en) 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
WO1999043299A2 (en) * 1998-02-26 1999-09-02 Abbott Laboratories Oral formulation for hydrophilic drugs
JP2002531518A (ja) * 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
AU5936400A (en) 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
AU3885201A (en) * 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
WO2003035095A1 (en) * 2001-10-19 2003-05-01 Maxim Pharmaceuticals, Inc. Use of histamine to treat liver disease
US20030215462A1 (en) * 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
EP2218448B1 (de) 2002-12-13 2015-09-23 Durect Corporation Orale Darreichungsform mit flüssigen hochviskose Trägersystemen
EP1587521A1 (de) * 2003-01-30 2005-10-26 Council of Scientific and Industrial Research Bioverfügbarkeit erhöhende aktiviteit von carum carvi extrakten und deren fraktionen
CA2521221A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics, Inc. Method for the treatment of prostate cancer
EP1660039B1 (de) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prävention von molekulargewichtreduktion des polymers, bildung von unreinheiten und gelierung in polymer-zusammensetzungen
JP4388322B2 (ja) * 2003-07-31 2009-12-24 花王株式会社 アポリポプロテインd分解抑制剤
WO2005060960A2 (en) * 2003-12-11 2005-07-07 Maxim Pharmaceuticals, Inc. Use of histamine to treat bone disease
CA2568201C (en) 2004-05-24 2013-07-30 Universitat Zu Koln Identification of ergothioneine transporter and therapeutic uses thereof
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2067471B1 (de) 2007-12-06 2018-02-14 Durect Corporation Orale arzneimitteldosierformen
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
NO3085381T3 (de) 2008-05-21 2018-09-15
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーSpotlight Technology Partners Llc 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
CN113329680A (zh) 2018-11-02 2021-08-31 营养21有限责任公司 用于改善视频游戏者认知功能的含有肌醇稳定的精氨酸硅酸盐复合物和肌醇的组合物
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4382922A (en) * 1980-08-29 1983-05-10 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4632979A (en) * 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
AU5157590A (en) * 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration

Also Published As

Publication number Publication date
DK0601053T3 (da) 2001-01-08
GR3035116T3 (en) 2001-03-30
DE69231536T2 (de) 2001-06-13
AU669856B2 (en) 1996-06-27
CA2103163A1 (en) 1993-03-04
KR100256715B1 (ko) 2000-05-15
US5284657A (en) 1994-02-08
IL102857A (en) 1997-02-18
EP0601053B1 (de) 2000-10-25
EP0601053A1 (de) 1994-06-15
PT100812B (pt) 1999-07-30
WO1993003751A1 (en) 1993-03-04
ES2153362T3 (es) 2001-03-01
PT100812A (pt) 1993-09-30
DE69231536D1 (de) 2000-11-30
IL102857A0 (en) 1993-01-31
JPH06510046A (ja) 1994-11-10
CA2103163C (en) 1998-10-20
EP0601053A4 (en) 1996-07-17
AU2519392A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
DE69231536D1 (de) Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
FI883739A0 (fi) Menetelmä terapeuttisesti aktiivisten fenoksi-indaanimetyyliamiinijohdannaisten valmistamiseksi
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DK0686151T3 (da) Substituerede cycliske carbonylforbindelser og derivater deraf, der kan anvendes som retrovirale proteaseinhibitorer
NO923142L (no) Cykliske peptider og anvendelse derav
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
GT199700009AA (es) Terapia combinada para la osteoporosis
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
ATE102039T1 (de) Rinderfaktor-xa-hemmender faktor und diesen enthaltende pharmazeutische zusammensetzungen.
DE69924846D1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
DK434884A (da) Benzothiopen-derivater til anvendelse som midler mod astma samt farmaceutiske formuleringer indeholdende saadanne derivater
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
JPS5753414A (en) Stabilized medicinal composition
DK598288A (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DK0397556T3 (da) N-Phenylamider, fremgangsmåder til fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE3778826D1 (de) Bestaendige therapeutische zusammensetzungen, basierend auf hydrophobem pflanzlichem oel und verfahren zu ihrer herstellung.
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
NO922635D0 (no) Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
AU628492B2 (en) Improvements in chemical compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee